Barclays raised the firm’s price target on Legence (LGN) to $37 from $34 and keeps an Equal Weight rating on the shares. The company reported a Q3 beat but its leverage still limits some comparable upside, the analyst tells investors in a research note.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LGN:
- Legence price target raised to $45 from $40 at BTIG
- Legence Corp. Receives Buy Rating Amid Strong Financial Performance and Strategic Growth Initiatives
- Legence Corp. Reports Strong Q3 2025 Results and Strategic Acquisitions
- Midday Fly By: Walmart names new CEO, Merck acquires Cidara
- Legence Corp. Acquires Bowers Group for $475 Million